224 related articles for article (PubMed ID: 32626933)
1. High expression of FUSE binding protein 1 in breast cancer stimulates cell proliferation and diminishes drug sensitivity.
Liu W; Xiong X; Chen W; Li X; Hua X; Liu Z; Zhang Z
Int J Oncol; 2020 Aug; 57(2):488-499. PubMed ID: 32626933
[TBL] [Abstract][Full Text] [Related]
2. RNA-binding protein NONO contributes to cancer cell growth and confers drug resistance as a theranostic target in TNBC.
Kim SJ; Ju JS; Kang MH; Eun JW; Kim YH; Raninga PV; Khanna KK; Győrffy B; Pack CG; Han HD; Lee HJ; Gong G; Shin Y; Mills GB; Eyun SI; Park YY
Theranostics; 2020; 10(18):7974-7992. PubMed ID: 32724453
[TBL] [Abstract][Full Text] [Related]
3. ISL1 promotes cancer progression and inhibits cisplatin sensitivity in triple-negative breast cancer cells.
Zhang Y; Wang L; Gao P; Sun Z; Li N; Lu Y; Shen J; Sun J; Yang Y; Dai H; Cai H
Int J Mol Med; 2018 Nov; 42(5):2343-2352. PubMed ID: 30226569
[TBL] [Abstract][Full Text] [Related]
4. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer.
Li M; Li A; Zhou S; Lv H; Yang W
J Hematol Oncol; 2019 Feb; 12(1):14. PubMed ID: 30736840
[TBL] [Abstract][Full Text] [Related]
5. Knockdown of SASS6 reduces growth of MDA‑MB‑231 triple‑negative breast cancer cells through arrest of the cell cycle at the G2/M phase.
Du L; Jing J; Wang Y; Xu X; Sun T; Shi Y; Wang W; Tian B; Han C; Zhao X; Chang H
Oncol Rep; 2021 Jun; 45(6):. PubMed ID: 33907854
[TBL] [Abstract][Full Text] [Related]
6. RNA-binding protein MSI2 isoforms expression and regulation in progression of triple-negative breast cancer.
Li M; Li AQ; Zhou SL; Lv H; Wei P; Yang WT
J Exp Clin Cancer Res; 2020 May; 39(1):92. PubMed ID: 32448269
[TBL] [Abstract][Full Text] [Related]
7. Increased expression of biological markers as potential therapeutic targets in Saudi women with triple-negative breast cancer.
Sayed-Ahmed MM; Hafez MM; Al-Shabanah OA; Al-Rejaie SS; Aleisa AM; Al-Yahya AA; Alsheikh A; Al Diab AI; Al-Akeely MH
Tumori; 2013; 99(4):545-54. PubMed ID: 24326846
[TBL] [Abstract][Full Text] [Related]
8. PSMB5 is associated with proliferation and drug resistance in triple-negative breast cancer.
Wei W; Zou Y; Jiang Q; Zhou Z; Ding H; Yan L; Yang S
Int J Biol Markers; 2018 Jan; 33(1):102-108. PubMed ID: 28623645
[TBL] [Abstract][Full Text] [Related]
9. Cancer Testis Antigen Promotes Triple Negative Breast Cancer Metastasis and is Traceable in the Circulating Extracellular Vesicles.
Kannan A; Philley JV; Hertweck KL; Ndetan H; Singh KP; Sivakumar S; Wells RB; Vadlamudi RK; Dasgupta S
Sci Rep; 2019 Aug; 9(1):11632. PubMed ID: 31406142
[TBL] [Abstract][Full Text] [Related]
10. Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin.
Liang S; Peng X; Li X; Yang P; Xie L; Li Y; Du C; Zhang G
Oncotarget; 2015 Jan; 6(2):1020-30. PubMed ID: 25544759
[TBL] [Abstract][Full Text] [Related]
11. Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51.
Lee JO; Kang MJ; Byun WS; Kim SA; Seo IH; Han JA; Moon JW; Kim JH; Kim SJ; Lee EJ; In Park S; Park SH; Kim HS
Breast Cancer Res; 2019 Oct; 21(1):115. PubMed ID: 31640742
[TBL] [Abstract][Full Text] [Related]
12. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
[TBL] [Abstract][Full Text] [Related]
13. DCAF13 promotes triple-negative breast cancer metastasis by mediating DTX3 mRNA degradation.
Liu J; Li H; Mao A; Lu J; Liu W; Qie J; Pan G
Cell Cycle; 2020 Dec; 19(24):3622-3631. PubMed ID: 33300431
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Notch1 reverses EMT and chemoresistance to cisplatin via direct downregulation of MCAM in triple-negative breast cancer cells.
Zeng D; Liang YK; Xiao YS; Wei XL; Lin HY; Wu Y; Bai JW; Chen M; Zhang GJ
Int J Cancer; 2020 Jul; 147(2):490-504. PubMed ID: 32020593
[TBL] [Abstract][Full Text] [Related]
15. Knockdown of THOC1 reduces the proliferation of hepatocellular carcinoma and increases the sensitivity to cisplatin.
Cai S; Bai Y; Wang H; Zhao Z; Ding X; Zhang H; Zhang X; Liu Y; Jia Y; Li Y; Chen S; Zhou H; Liu H; Yang C; Sun T
J Exp Clin Cancer Res; 2020 Jul; 39(1):135. PubMed ID: 32669125
[TBL] [Abstract][Full Text] [Related]
16. Targeting LC3 and Beclin-1 autophagy genes suppresses proliferation, survival, migration and invasion by inhibition of Cyclin-D1 and uPAR/Integrin β1/ Src signaling in triple negative breast cancer cells.
Hamurcu Z; Delibaşı N; Geçene S; Şener EF; Dönmez-Altuntaş H; Özkul Y; Canatan H; Ozpolat B
J Cancer Res Clin Oncol; 2018 Mar; 144(3):415-430. PubMed ID: 29288363
[TBL] [Abstract][Full Text] [Related]
17. CELF6 modulates triple-negative breast cancer progression by regulating the stability of FBP1 mRNA.
Yang X; Zhao L; Pei J; Wang Z; Zhang J; Wang B
Breast Cancer Res Treat; 2020 Aug; 183(1):71-82. PubMed ID: 32601971
[TBL] [Abstract][Full Text] [Related]
18. microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression.
Guo GC; Wang JX; Han ML; Zhang LP; Li L
Cell Oncol (Dordr); 2017 Apr; 40(2):157-166. PubMed ID: 28054302
[TBL] [Abstract][Full Text] [Related]
19. Tocilizumab potentiates cisplatin cytotoxicity and targets cancer stem cells in triple-negative breast cancer.
Alraouji NN; Al-Mohanna FH; Ghebeh H; Arafah M; Almeer R; Al-Tweigeri T; Aboussekhra A
Mol Carcinog; 2020 Sep; 59(9):1041-1051. PubMed ID: 32537818
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of SERPINA3 promotes tumor invasion and migration, epithelial-mesenchymal-transition in triple-negative breast cancer cells.
Zhang Y; Tian J; Qu C; Peng Y; Lei J; Li K; Zong B; Sun L; Liu S
Breast Cancer; 2021 Jul; 28(4):859-873. PubMed ID: 33569740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]